SVF
Level A· Stronger Clinical EvidenceSystematic ReviewPubMed

Bone marrow concentrated cells and stromal vascular fraction cells injections for osteoarthritis treatment: a systematic review.

Vadalà G., Papalia R., La Verde L., Russo F., Denaro V., Rosa MA.

Systematic Review with a reported sample of 1332 on Osteoarthritis, published in J Biol Regul Homeost Agents (2016) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
J Biol Regul Homeost Agents (2016)
Country
Singapore
Reported sample size
1332
Source database
PubMed
PMID
28002902
Citations
1

Abstract (original English)

The aim of this systematic review is to examine current clinical evidences supporting the intraarticular injection of bone marrow concentrate cells (BMC) and adipose-derived stromal vascular fraction cells (SVF) for the treatment of osteoarthritis (OA). The research was performed on PubMed (Medline), EMBASE and Cochrane Library considering the English literature. Only clinical trials have been included. The systematic research identified twelve clinical trials. Articles included in the study, were one of level II, four of level III, six of level IV and one level V. Among clinical trials, none were randomized, four were comparative, seven were case series, and one was a case report. Seven studies were focused on the use of SVF (1332 patients) and five on the use of BMC (963 patients), with preliminary interesting findings in the OA treatment. Despite the growing interest in this biological approach for OA, knowledge on this topic is still preliminary. Randomized controlled trials are needed to support the potential of BMC and SVF injections and to evaluate advantages and disadvantages with respect to the available treatments.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Adipose TissueBone Marrow CellsBone Marrow TransplantationHumansInjections, Intra-ArticularOsteoarthritisStromal Cells
Osteoarthritis
View on PubMed

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “bone marrow concentrated”View all: author vadalàView all: year 2016

Related research